



III FÓRUM ONCOGUIA DE CÂNCER DE PULMÃO



Quando a recomendação da Conitec
não significa acesso
Case Câncer de Pulmão

André Santos

Fundador do cliqueSUS
e Gerente de Dados e RWE no Oncoguia

cliqueSUS

instituto
Oncoguia
10

PATTERNS OF THERAPY FOR EGFR+ NON-SMALL CELL LUNG CANCER IN THE BRAZILIAN PUBLIC SYSTEM: WHEN APPROVAL DOES NOT MEAN ACCESS

Marcelo R S Cruz MD, MSc¹, Andre M dos Santos², Luciana Holtz³

¹Hospital Sírio-Libanês, ²CliqueSUS, ³Instituto Oncoguia
e-mail: andre@atsaude.com.br


INTRODUCTION

In Brazil, a total of 18,740 (the second most common) and 12,530 (the fourth most common) new cases of lung cancer are estimated among men and women, respectively, for the year of 2018. This corresponds to an estimated risk of 18.16 new cases per 100,000 men and an estimated risk of 11.81 new cases per 100,000 women. Lung cancer is considered the most deadly type of cancer, in 2017, this cancer killed 16,137 (14% of the total of neoplasm deaths) men and 16,724 women (16.1% of the total of neoplasm deaths)¹. Targeted therapies, such as the first generation EGFR tyrosine kinase inhibitors Erlotinib and Gefitinib, became important treatment options for patients with EGFR+ advanced non-small cell lung cancer.

II Semana Brasileira da Oncologia

22/10/2019 a 26/10/2019

SBOC



INCORPORAÇÃO BASEADA EM EVIDÊNCIAS



Erlotinibe para câncer de
pulmão de células não
pequenas


Novembro de 2013

Gefitinibe para câncer
de pulmão de células
não pequenas em
primeira linha

Novembro de 2013




DATASUS
QUIMIOTERAPIA




JAN/2015 a
DEZ/2018




BRASIL



DE-PARA DOS
ESQUEMAS
TERAPÊUTICOS



227.000



38.000


RESULTADOS

III FÓRUM ONCOGUIA
DE CÂNCER DE PULMÃO

● GEFITINIBE ● ERLOTINIBE

GEFITINIBE
2,4%

ERLOTINIBE
0,9%



61%

pacientes apresentaram
estadiamento IV

GEFITINIBE

3,3%

ERLOTINIBE

1,2%

Nosso desafio vai **muito além da incorporação**,
após essa etapa ainda temos o **desafio do acesso** a essas
medicações para os pacientes elegíveis